Activation of PKG has emerged as a clinical strategy for the treatment of HF, with cGMP-augmenting medications, such as nitrates (3, 47), neprilysin inhibitors (4), and guanylate cyclase stimulators (5), demonstrating efficacy in HF with reduced ejection fraction. This evidence concerns the gene MME and hydrops fetalis.